Research Summary

Dr. Apollonio is Professor in the Department of Clinical Pharmacy at the University of California, San Francisco. She has served as an instructor and research mentor in the UCSF School of Pharmacy since 2004, and has earned multiple teaching awards. Her research focus is the translation of research into policy. She is particularly interested in the political and marketing activities of industries implicated in the spread of non-communicable diseases, which include tobacco, pharmaceuticals, cannabis, alcohol, and food. Her recent work addresses tobacco control in vulnerable populations, the combined use of tobacco and cannabis, the spread of laws addressing new tobacco and cannabis delivery systems, and policies that allow substitution of cannabis for opiates. Her research also considers the ways that clinical findings are used in developing policy interventions and communicating knowledge from scientists to the public, and identifies methods to increase the role of evidence in making public health policy decisions. The analysis underlying these findings relies on multiple data sources (including clinical research findings, surveillance datasets, internal industry documents, administrative datasets, and interviews) and uses both qualitative and quantitative methods to identify how policies affecting public health are made. Her work has been published in journals across disciplines, including law, medicine, pharmacy, political science, public health, and public policy. Her training includes a postdoctoral appointment at the UCSF Center for Tobacco Control Research and Education, a Ph.D. in Political Science from the University of California, Berkeley, and a Master in Public Policy from Harvard University.

Research Funding

  • July 1, 2021 - June 30, 2023 - California cannabis poisonings under Proposition 64 , Principal Investigator . Sponsor: California Bureau of Cannabis Control, Sponsor Award ID: RG-1603070583-553
  • July 1, 2020 - June 30, 2023 - Effect of minimum floor price laws on tobacco consumption , Co-Investigator . Sponsor: California Tobacco-Related Disease Research Program, Sponsor Award ID: 31KT-1894
  • January 1, 2022 - December 31, 2022 - Characterizing online tobacco product marketing , Principal Investigator . Sponsor: US Food and Drug Administration Tobacco Centers of Regulatory Science, Sponsor Award ID: U54CA180890 (pilot)
  • January 1, 2021 - December 31, 2021 - Effect of local tobacco flavor bans on consumption , Principal Investigator . Sponsor: US Food and Drug Administration Tobacco Centers of Regulatory Science, Sponsor Award ID: U54CA180890 (pilot)

Education

Macalester College, St. Paul, MN, BA, 1992, Political Science, History
Harvard Kennedy School, Cambridge, MA, MPP, 1994, Health Policy
University of California, Berkeley, CA, PhD, 2003, Political Science
University of California, San Francisco, CA, Postdoctoral, 2003-2006, Health Policy

Honors & Awards

  • 1995
    Henry Robert Braden Fellowship, UC Berkeley
  • 2000-2001
    Graduate Dissertation Fellowship, UC Berkeley
  • 2003-2005
    American Legacy Foundation Fellowship, UCSF School of Medicine
  • 2005
    Certificate in Health Services Research, UCSF School of Medicine
  • 2008
    Academic Senate Travel Grant, UCSF
  • 2008
    Dean's Recognition for Excellence in Teaching Award, UCSF School of Pharmacy
  • 2009
    Regulation and Governance Prize for the best article published in the journal in 2007 or 2008

Selected Publications

  1. Banawis, Micah
    Mah, Gordon
    Mohsin, Rania
    Pobre, Jethro
    Tracy, Darrin
    Song, Anna V
    Apollonio, Dorie E . An observational study of the extent of naloxone furnishing in California Central Valley community pharmacies. Journal of the American Pharmacists Association. 2022.  View on PubMed
  2. Yakubi H, Gac B, Apollonio DE. Industry strategies to market opioids to children and women in the USA: a content analysis of internal industry documents from 1999 to 2017 released in State of Oklahoma v. Purdue Pharma, L.P. et al. BMJ Open. 2022 Nov 02; 12(11):e052636.  View on PubMed
  3. Apollonio DE. Marketing Antipsychotics to Correctional Facilities: A Review of Pharmaceutical Industry Documents. J Correct Health Care. 2022 Oct 03.  View on PubMed
  4. Matthay EC, Mousli LM, Fu C, Zhang S, Ponicki WR, Gruenewald P, Apollonio DE, Schmidt LA. Equity in Coverage of Local Cannabis Control Policies in California, 2020‒2021. Am J Public Health. 2022 Nov; 112(11):1640-1650.  View on PubMed
  5. Wakefield T, Glantz SA, Apollonio DE. Content Analysis of the Corporate Social Responsibility Practices of 9 Major Cannabis Companies in Canada and the US. JAMA Netw Open. 2022 08 01; 5(8):e2228088.  View on PubMed
  6. Yakubi H, Gac B, Apollonio DE. Marketing Opioids to Veterans and Older Adults: A Content Analysis of Internal Industry Documents Released from State of Oklahoma v. Purdue Pharma LP, et al. J Health Polit Policy Law. 2022 08 01; 47(4):453-472.  View on PubMed
  7. Caleb Alexander G, Mix LA, Choudhury S, Taketa R, Tomori C, Mooghali M, Fan A, Mars S, Ciccarone D, Patton M, Apollonio DE, Schmidt L, Steinman MA, Greene J, Ling PM, Seymour AK, Glantz S, Tasker K. The Opioid Industry Documents Archive: A Living Digital Repository. Am J Public Health. 2022 08; 112(8):1126-1129.  View on PubMed
  8. Matthay EC, Mousli L, Ponicki WR, Glymour MM, Apollonio DE, Schmidt LA, Gruenewald P. A Spatiotemporal Analysis of the Association of California City and County Cannabis Policies with Cannabis Outlet Densities. Epidemiology. 2022 Sep 01; 33(5):715-725.  View on PubMed
  9. Choi AJ, Hean AC, Lee JK, Tran ND, Lin TK, Apollonio DE. A Retrospective Global Assessment of Factors Associated With COVID-19 Policies and Health Outcomes. Front Public Health. 2022; 10:843445.  View on PubMed
  10. Carlson Z, Pham S, El-Sokkary J, Apollonio DE. Cannabis use prevalence among Baby Boomers before and after implementation of recreational retail sales in California. Subst Abuse Treat Prev Policy. 2022 03 05; 17(1):17.  View on PubMed
  11. Hartman-Filson M, Chen J, Lee P, Phan M, Apollonio DE, Kroon L, Donald F, Vijayaraghavan M. A community-based tobacco cessation program for individuals experiencing homelessness. Addict Behav. 2022 06; 129:107282.  View on PubMed
  12. Rotering T, Apollonio DE. Cannabis industry lobbying in the Colorado state legislature in fiscal years 2010-2021. Int J Drug Policy. 2022 04; 102:103585.  View on PubMed
  13. Roth W, Tam M, Bi C, Kim J, Lewis J, Ho R, Apollonio DE. Changes in California cannabis exposures following recreational legalization and the COVID-19 pandemic. Clin Toxicol (Phila). 2022 May; 60(5):632-638.  View on PubMed
  14. Bellman R, Mohebbi S, Nobahar N, Parizher J, Apollonio DE. An observational survey assessing the extent of PrEP and PEP furnishing in San Francisco Bay Area pharmacies. J Am Pharm Assoc (2003). 2022 Jan-Feb; 62(1):370-377.e3.  View on PubMed
  15. Driller G, Plasencia E, Apollonio DE. Retrospective review of nicotine exposures in California from 2012 to 2018 and analysis of the impacts of e-cigarette regulations. BMJ Open. 2021 03 02; 11(3):e043133.  View on PubMed
  16. Apollonio DE, Dutra LM, Glantz SA. Associations between smoking trajectories, smoke-free laws and cigarette taxes in a longitudinal sample of youth and young adults. PLoS One. 2021; 16(2):e0246321.  View on PubMed
  17. Vijayaraghavan M, Elser H, Frazer K, Lindson N, Apollonio D. Interventions to reduce tobacco use in people experiencing homelessness. Cochrane Database Syst Rev. 2020 12 03; 12:CD013413.  View on PubMed
  18. Chen L, Lim J, Jeong A, Apollonio DE. Implementing law into practice: hormonal contraceptive furnishing in San Francisco community pharmacies. Birth Control Pharmacist. 2020.  View on PubMed
  19. Nguyen AM, Kearney TE, Apollonio DE. Evaluation of naloxone furnishing community pharmacies in San Francisco. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):1050-1057.e1.  View on PubMed
  20. Wu A, Phan C, Nguyen KC, Quindoy M, Lewis J, Apollonio DE. Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling. Clin Toxicol (Phila). 2021 Apr; 59(4):313-319.  View on PubMed

Go to UCSF Profiles, powered by CTSI